

1

2 **Neuron loss in the brain starts in childhood, increases exponentially with age and is halted by GM-CSF**
3 **treatment in Alzheimer's disease**

4

5

6 Stefan H. Sillau,^{1†} Christina Coughlan,^{1,2†} Md. Mahiuddin Ahmed,^{1,2†} Kavita Nair,^{1,3} Paula Araya,² Matthew
7 D. Galbraith,^{2,4} Brianne M. Bettcher,^{1,2} Joaquin M. Espinosa,^{2,4} Heidi J. Chial,^{1,2} Neill Epperson,⁵ Timothy
8 D. Boyd,^{1,2} Huntington Potter^{1,2*}

9

10 1. Department of Neurology and the University of Colorado Alzheimer's and Cognition Center, University
11 of Colorado Anschutz Medical Campus, Aurora, CO

12 2. Linda Crnic Institute for Down Syndrome, University of Colorado, Anschutz Medical Campus, Aurora,
13 CO

14 3. Department of Clinical Pharmacy, Center for Pharmaceutical Outcomes Research (CePOR)

15 4. Department of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, CO

16 5. Department of Psychiatry, University of Colorado Anschutz Medical Campus, Aurora, CO

17

18 †These authors contributed equally to this work: S. H. Sillau, C. Coughlan, and Md. M. Ahmed

19 *Corresponding author: H. Potter (Huntington.Potter@cuanschutz.edu)

20

21

22

23

24

25 **Summary**

26 Aging increases the risk of neurodegeneration, cognitive decline, and Alzheimer's disease (AD). Currently
27 no means exist to measure neuronal cell death during life or to prevent it. Here we show that cross-sectional
28 measures of human plasma proteins released from dying/damaged neurons (ubiquitin C-terminal hydrolase-
29 L1/UCH-L1 and neurofilament light/NfL) become exponentially higher from age 2-85; UCH-L1 rises faster
30 in females. Glial fibrillary acidic protein (GFAP) concentrations, indicating astrogliosis/inflammation,
31 increase exponentially after age 40. Treatment with human granulocyte-macrophage colony-stimulating
32 factor (GM-CSF/sargramostim) halted neuronal cell death, as evidenced by reduced plasma UCH-L1
33 concentrations, in AD participants to levels equivalent to those of five-year-old healthy controls. The ability
34 of GM-CSF treatment to reduce neuronal apoptosis was confirmed in a rat model of AD. These findings
35 suggest that the exponential increase in neurodegeneration with age, accelerated by neuroinflammation, may
36 underlie the contribution of aging to cognitive decline and AD and can be halted by GM-CSF/sargramostim
37 treatment.

38

39 **Key words:** Aging, Neurodegeneration, Alzheimer, granulocyte-macrophage colony stimulating factor,
40 ubiquitin C-terminal hydrolase-L1, neurofilament light, glial fibrillary acidic protein, senolysis,
41 neuroprotection

42

43

44 **Acknowledgements**

45 National Institutes of Health grant R01AG071151 (HP)

46 National Institutes of Health grant R01AI50305, (JE)

47 The State of Colorado (HP)

48 Alzheimer's Association Part the Cloud grant PTC C-16-422172 (HP)

49 The Global Down Syndrome Foundation (HP, JME)

50 The Anna and John J. Sie Foundation (JME)

51 The University of Colorado Human Immunology and Immunotherapy Initiative (HI3).

52

53 **Author contributions:**

54 Conceptualization: HP, SHS, NE, HJC

55 Methodology: SHS, CC, MMA, KN, BMB

56 Investigation: SHS, CC, MMA, KN, PA, MDG, BMB, JME

57 Supervision: HP, JME

58 Writing—original draft: HP

59 Writing—review & editing: HJC, SHS, CC, MMA, BMB, HP, TDB

60

61 **Declaration of interests:**

62 HP, TDB, and SHS are inventors on several non-licensed U.S. patents or pending applications owned by the

63 University of South Florida or the University of Colorado and related to this research. TDB's contributions to

64 this work occurred during his employment at the University of Colorado, and he is now employed and owns

65 stock options at Partner Therapeutics. All other authors declare they have no competing interests.

66

67 **Declaration of generative AI and AI-assisted technologies**

68 None used.

69

70 **Data and materials availability:** All data are available in the main text or the supplementary materials.

71

72

73 **Introduction**

74 Increasing age is the greatest risk factor for ‘natural’ age-associated cognitive decline (AACD) and,
75 especially in females, for developing Alzheimer’s disease (AD), but the mechanisms underlying this
76 connection are unknown¹⁻¹⁰. Neuronal loss and brain atrophy accompany aging and AD and can reasonably
77 be inferred to lead to cognitive deficits¹¹⁻¹⁴. Increased inflammation is also correlated with AD pathogenesis
78 and aging (termed ‘inflammaging’), but whether inflammation causes and/or is a response to
79 neurodegeneration is also unknown^{1,8,15-17}. For example, early studies of patients with the inflammatory
80 disease rheumatoid arthritis (RA) found that they exhibited a reduced risk of developing AD, which was
81 attributed to their use of non-steroidal anti-inflammatory drugs (NSAIDs). However, studies of other
82 inflammatory diseases, such as periodontitis, detected an increase in AD risk, and NSAID treatment in
83 clinical trials showed no benefit to participants with either AD or mild cognitive impairment (MCI) (for
84 discussion see^{16,18,19}). Evidently, the role of inflammation in aging and neurodegenerative disease is
85 complex.

86

87 The identification of biomarkers of brain aging and the underlying mechanism(s) that they reflect are
88 essential to advancing the development and testing of therapies for AD and for the more complex AACD
89^{17,20-23}. Here we assessed two proteins that reflect neuronal loss (UCH-L1) and axonal damage (NfL) and find
90 that their plasma concentrations become exponentially higher throughout life starting from age 2.
91 Furthermore, astrogliosis, measured by plasma concentrations of GFAP, becomes exponentially higher
92 starting at age 40 and is thus likely to be reactive to rather than causal of neurodegeneration during aging and
93 reflect a positive feedback loop that underlies the exponential nature of the increases in all three biomarkers
94 of brain damage with age. Finally, we report that GM-CSF/sargramostim, a long-approved drug for
95 stimulating immune stem cells in patients with leukopenia, which we previously found to improve cognition
96 and biomarkers of neurodegeneration in a clinical trial of mild-to-moderate Alzheimer’s disease, effectively
97 reverses the rate of neuronal loss in trial participants to the very low levels observed in early childhood in the
98 current study. We also found that GM-CSF treatment reduces neuronal apoptosis in the hippocampi of aged

99 TgF344-AD rats, a model that recapitulates all human AD brain neuropathology. These findings in humans
100 and animals add biological significance to the statistically significant finding in the clinical trial.

101

102 **Results**

103 **Biomarkers of Neurodegeneration.** To identify biomarkers of neuronal cell loss or damage during brain
104 aging, we focused on UCH-L1 and NfL because of numerous reports that their plasma concentrations are
105 well correlated with neuronal damage in, for example, neurodegenerative disease and traumatic brain injury
106 (TBI)²⁴⁻²⁹. Although UCH-L1 was initially discovered and named as a ubiquitin C-terminal hydrolase, it is
107 likely that this is not its primary function, especially in neurons, as cells and animals lacking UCH-L1 are not
108 defective in the ubiquitin proteasome system^{25,30}. Indeed, UCH-L1 is primarily a brain protein, making up 1-
109 5% of the total protein in neurons, with some expression in endocrine tissue^{25,26}. Suggestions for the
110 neuronal function of UCH-L1 include the regulation of energy metabolism and mitochondrial fusion,
111 antioxidant activity, and synaptic activity^{26,30,31}. Regardless of its function, an increased concentration of
112 UCH-L1 in the plasma is a sensitive and rapidly-responding measure of acute neuronal cell
113 damage/degeneration after TBI, and UCH-L1 expression is greatly reduced in the AD brain, possibly due to
114 loss of neurons or neuronal activity²⁴⁻²⁷. NfL is an intermediate filament protein in neurons and an essential
115 component of axons. Traumatic or disease-associated damage to axon tracks leads to the release of NfL into
116 the cerebrospinal fluid (CSF) and ultimately into the plasma where it can be detected as a biomarker of
117 axonal damage in numerous neurodegenerative diseases as well as in TBI^{25,28,32}.

118

119 **Plasma concentrations of UCH-L1 are exponentially higher with age from early childhood.** Plasma
120 concentrations of UCH-L1, a measure of neuronal cell loss, were assessed in 317 healthy control participants
121 between age 2 and 85 from three observational studies. These included 103 healthy control participants from
122 the Human Trisome Project (HTP) of the Linda Crnic Institute for Down Syndrome (i.e., healthy controls
123 without Down syndrome (DS)), 69 healthy control participants from the University of Colorado Alzheimer's

124 and Cognition Center (CUACC) study of the role of inflammation in AD (termed Bio-AD)¹⁷, and 145
125 healthy control participants from the multiple sclerosis (MS) biomarker study (see demographics in
126 Methods). The assessments were determined using the Quanterix SIMOA[®] platform, which was also used
127 previously to assess plasma biomarkers in the “sargramostim/GM-CSF AD trial” in participants with mild-
128 to-moderate AD³³. As shown in **Figure 1A**, plasma UCH-L1 concentrations increase exponentially with age
129 across the entire age spectrum, from an estimated 6.22 pg/ml at age 2 to approximately 15.56 pg/ml at age 85
130 (estimated change per year = 1.110%, 95% CI: (0.716%, 1.505%), $p = 5.504 \times 10^{-8}$). Graphical inspection
131 of the data, and comparison to a spline fit (**Supplementary Figure 1A**), indicate that a log-linear relationship
132 of UCH-L1 concentrations with age is an excellent fit (Pearson correlation estimate (replicates log averaged)
133 = 0.30, 95% CI: (0.20, 0.40)), which is equivalent to an exponential relationship on the original scale (**Figure**
134 **1A and 1B**). Interestingly, most of the age-associated increase in plasma concentrations of UCH-L1 occurs
135 in females (**Figure 1C**, estimated female change per year = 1.448%, 95% CI: (0.942%, 1.957%), $p = 3.635 \times$
136 10^{-8} ; estimated male change per year = 0.582%, 95% CI: (-0.036%, 1.203%), $p=0.0650$; sex difference
137 $p=0.0342$; estimate of the ratio of ratios = 0.99146, 95% CI: (0.98362, 0.99936)). The log plots in **Figure 1D**
138 and the spline analyses (**Supplementary Figure 1B**) support the conclusion that the plasma concentration of
139 UCH-L1 increases exponentially with age in males and females. Because plasma UCH-L1 is primarily
140 derived from damaged brain neurons, its concentration in plasma provides a minimal estimate of the ongoing
141 neuronal cell death in the brain with age (**Supplementary Figure 2**).

142

143


144

145

146

147

148



149 **Figure 1.**

150 **Figure 1. Plasma UCH-L1 concentrations are higher with advancing age in healthy control**
151 **participants, especially in females.**


152 Concentrations of UCH-L1 in plasma from 314 healthy control participants who were part of either the Crnic
153 Institute Human Trisome Project (n=103), the CUACC Bio-AD longitudinal observational study (n=69), or
154 the MS healthy controls biomarker study (n=145) (3 participants lacked usable UCH-L1 data) were
155 compared to the age of the participant. Together, these three healthy control cohorts span ages 2-85. The
156 association between absolute UCH-L1 concentrations and age and the point wise standard errors are shown
157 in (A). The UCH-L1 log plot with point wise standard errors is shown in (B). The data show that plasma
158 UCH-L1 levels are exponentially higher with age across the lifespan (estimated change per year=1.110%,
159 95% CI: (0.716%, 1.505%), $p = 5.504 * 10^{(-8)}$). The effect of sex on the curve is shown in (C), which
160 indicates that the majority of the promotion effect of age on plasma UCH-L1 concentrations are driven by
161 females (estimated female change per year=1.448%, 95% CI: (0.942%, 1.957%), $p = 3.635 * 10^{(-8)}$;
162 estimated male change per year=0.582%, 95% CI: (-0.036%, 1.203%), $p=0.0650$; sex difference $p=0.0342$;
163 sex ratio of ratios = 0.99146, 95% CI: (0.98362, 0.99936), $p=0.0342$). The effect of sex on the UCH-L1 log
164 plot with point wise standard errors is shown in (D). The associations between absolute UCH-L1
165 concentrations and age and the point wise standard errors are shown. For the age range of 40-83 years, the
166 area under the curve (AUC) average for the expected UCH-L1 values in males was statistically significantly
167 less than the expected values in females (ratio estimate = 0.792, 95% CI: (0.628, 0.997), p value = 0.0472).
168 Because the age effects in the model are linear in the log plot, the AUC average is equivalent to comparing
169 the expected value for males to females at the midpoint of the range, 61.5 years.
170

171 **Plasma concentrations of NfL are exponentially higher with age from early childhood.** Plasma

172 concentrations of NfL, which is released primarily from damaged axons, is commonly used to assess/stage
173 AD, MCI, and the risk of future cognitive decline^{22,28}. Therefore, we examined the effects of age and sex on
174 plasma concentrations of NfL in the 317 healthy control participants. As shown in **Figure 2A** and **2B**, plasma
175 concentrations of NfL were exponentially higher with increasing age in healthy control participants ($p <$
176 $2.220 * 10^{(-16)}$), with the slope of the log-transformed curve being greater than that observed for UCH-L1
177 with increasing age, such that NfL plasma concentrations are higher by 2.469% per cross-sectional year
178 (95% CI: (2.225%, 2.714%), $p < 2.220 * 10^{(-16)}$). Of note, the 95% confidence intervals for the NfL and
179 UCH-L1 rates of increase are non-overlapping, suggesting a statistically significant difference ($\alpha=0.05$)
180 between the two. The exponential curve of plasma NfL with age showed a trend of being steeper for males
181 than for females ($p = 0.0502$), with an estimated difference per year of 2.775% (95% CI: (2.388%, 3.164%),
182 $p < 2.220 * 10^{(-16)}$) for males, compared to an estimated difference per year of 2.277% (95% CI: (1.965%,
183 2.590%), $p < 2.220 * 10^{(-16)}$) for females (**Figure 2C**); estimate of ratio of ratios = 1.00487, 95% CI:
184 (1.00000, 1.00976), $p=0.0502$.

185
186
187

Figure 2.



200

207

208

209

210

211

212

213

214

215


Figure 2. Plasma concentrations of NfL are exponentially higher with age in healthy control participants.


Concentrations of NfL in plasma samples from the 317 healthy control participants who were part of the Human Trisome Project (HTP) (n=103), the Bio-AD longitudinal observational study (n=69), or the MS healthy controls biomarker study (n=145) were compared to the age and sex of the donor. The data show that plasma concentrations of NfL are exponentially higher with age across the entire lifespan ($p < 2.220 \times 10^{-16}$). The association between absolute NfL concentrations and age and the point wise standard errors are shown in (A) and the log plot is shown in (B) (estimated change per year=2.469% per year, 95% CI:

216 (2.225%, 2.714%), $p < 2.220 \times 10^{-16}$). Separate plots for plasma concentrations of NfL in males and
217 females are shown in (C). For NfL, the exponential rate of change determined cross-sectionally was
218 marginally statistically non-significantly greater in males than in females (ratio of ratios = 1.00487, 95% CI:
219 (1.00000, 1.00976), $p = 0.0502$); estimated change per year was 2.775% (95% CI: (2.388%, 3.164%), $p <$
220 2.220×10^{-16}) in males, compared to 2.277% per year (95% CI: (1.965%, 2.590%), $p < 2.220 \times 10^{-16}$)
221 in females. When comparing the log linear fit to splines for the association of NfL with age and sex in
222 healthy controls (replicates averaged), the graph suggests that the rate of increase accelerates somewhat with
223 older age, but a linear relationship is still an excellent approximation for all healthy controls
224 (**Supplementary Figure 1C**) and when males and females are examined separately (**Supplementary Figure**
225 **1D**).
226

227 **Plasma concentrations of GFAP are exponentially higher from age 40.** GFAP is upregulated in activated
228 astrocytes, and its increased concentration in CSF or plasma is a marker of reactive gliosis in aging,
229 neurodegenerative disease, and TBI^{17,27,34}. Both females and males in our combined three cohorts that span
230 ages 2-85 showed an apparent overall exponential age effect for plasma GFAP concentrations (**Figure 3A,**
231 **3B, and 3C**) for both sexes (estimated female change per year=1.803%, 95% CI: (1.431%, 2.177%), $p <$
232 2.220×10^{-16}); estimated male change per year=1.496%, 95% CI: (1.037%, 1.957%), $p = 4.240 \times 10^{-}$
233 10)), with no significant difference between males and females. Interestingly, spline modeling of the plasma
234 levels of GFAP (replicates averaged) show a deviation from linearity in the log plots in that the GFAP levels
235 show a U shape with a decline from age 2 to 25, a constant rate, and then an exponential rise only starting
236 from approximately age 40 (**Figure 3D**). The U shape spline plot is apparent for both sexes with females
237 apparently rising slightly faster with age (**Figure 3E**). These findings indicate that brain
238 astrogliosis/neuroinflammation follows and thus is likely a reaction to the earlier and ongoing age-associated
239 neurodegeneration.

240





242
243
244
245 **Figure 3. Plasma concentrations of GFAP are exponentially higher with age in healthy control**
246 **participants.**

247 Concentrations of GFAP in plasma samples from the 317 healthy control participants who were part of the
248 Human Trisome Project (HTP) (n=103), the Bio-AD longitudinal observational study (n=69), or the MS
249 healthy controls biomarker study (n=145) were compared to the age and sex of the donor. The data show that
250 plasma concentrations of GFAP are exponentially higher with age across the entire lifespan ($p < 2.220$
251 $\times 10^{-16}$). The association between absolute GFAP concentrations and age and the point wise standard
252 errors are shown in (A) and the log plot is shown in (B) (estimated change per year=1.696%, 95% CI:
253 (1.404%, 1.989%), $p < 2.220 \times 10^{-16}$). Separate plots for plasma concentrations of GFAP in males and
254 females are shown in (C). Both sexes showed an exponential age effect for GFAP (estimated female change
255 per year=1.803%, 95% CI: (1.431%, 2.177%), $p < 2.220 \times 10^{-16}$; estimated male change per
256 year=1.496%, 95% CI: (1.037%, 1.957%), $p = 4.240 \times 10^{-10}$), but there was not a statistically significant
257 difference in age effect between the sexes (ratio of ratios = 1.00302, 95% CI: (0.99720, 1.00889), $p=0.3088$).
258 We also compared the log linear fit to splines for the biomarker association with age in the healthy controls
259 (replicates averaged) in (D). The deviance test for comparing spline model to the null hypothesis of linear: p
260 value $< 2.2 \times 10^{-16}$. The evidence is against linearity with a large sample, with the graph suggesting
261 something of a U shape with GFAP concentrations accelerating significantly after age 40. A spline plot by
262 sex in the healthy controls (replicates averaged) also suggests a U shape with GFAP concentrations
263 accelerating significantly after age 40 in (E). Deviation from linearity is evidenced in the data from males
264 and females, with females apparently rising slightly faster with age.
265


266 **Correlation analyses of plasma measures of age-associated brain degeneration. Figure 4 shows the**

267 correlations of the measures of neurodegeneration (UCH-L1, NfL) and astrogliosis (GFAP) for all healthy

268 control participants from age 2 to 85. All three measures (UCH-L1:NfL, UCH-L1:GFAP, and NfL:GFAP)

269 are highly correlated with each other ($P < 10^{-11}$), indicating that brain aging across the lifespan reflects
270 parallel increases in neurodegeneration, both cellular and axonal, and astrogliosis/inflammation.

271
272 **Figure 4.**



273

C

292

293
294
295
296

297 **Figure 4: Correlations between plasma biomarkers of neurodegeneration and astrogliosis, UCH-L1,**
298 **NfL, and GFAP.**

299 Log transformed replicate measures of UCH-L1, NfL, and GFAP from all normal control participants, age 2-
300 85, were averaged over replicates and subjected to Pearson and Spearman correlation analyses and found to
301 be highly correlated with each other. (A) UCH-L1:NfL, PC=0.37951, 95% CI: (0.280616, 0.470436), P =
302 $3.157 * 10^{(-12)}$; (B) UCH-L1:GFAP, PC=0.42263, 95% CI: (0.327250, 0.509477), P = $4.441 * 10^{(-15)}$;
303 and (C) NfL:GFAP PC=0.63743, 95% CI: (0.567089, 0.698536), P < $2.220 * 10^{(-16)}$.
304

305 **Comparisons of plasma measures of age-associated brain neurodegeneration and inflammation in**
306 **MCI due to AD, mild-to-moderate AD, and healthy controls.**

307 AD dementia and its precursor, MCI due to AD, are both strongly associated with age and are accompanied
308 by neurodegeneration and astrogliosis in the brain¹⁷. Having established full age curves for plasma markers
309 of neurodegeneration (UCH-L1 and NfL) and astrogliosis/inflammation (GFAP), we compared these to the
310 age-associated concentrations of NfL, GFAP, and UCH-L1 in plasma samples from the 32 participants with
311 MCI due to AD from the Bio-AD study (MCI) and in plasma samples from 36 participants with mild-to-
312 moderate AD from our previously published GM-CSF/sargramostim clinical trial at baseline (Baseline AD
313 GM-CSF Study Pooled)³³ (**Figure 5**). A diagnosis of MCI or mild-to-moderate AD was associated with
314 higher overall levels of both NfL (**Figure 5A**) and GFAP (**Figure 5B**) compared to age-matched healthy
315 control participants. NfL concentrations were higher in participants with mild-to-moderate AD than in
316 participants with MCI, while there was no significant difference in GFAP concentrations between
317 participants with mild-to-moderate AD and participants with MCI at 67.8 years, which is the mean age for
318 the sargramostim/GM-CSF-treated mild-to-moderate AD participants (AD/HC estimate age 67.8: NfL: ratio
319 estimate = 1.852, 95% CI: (1.514, 2.265), p = $2.201 * 10^{(-7)}$; GFAP: ratio estimate = 1.842, 95% CI:
320 (1.539, 2.203), p = $4.169 * 10^{(-9)}$; MCI/HC estimate age 67.8: NfL: ratio estimate = 1.362, 95% CI: (1.104,
321 1.682), p=0.0050; GFAP: ratio estimate = 1.948, 95% CI: (1.473, 2.577), p = $2.230 * 10^{(-5)}$; AD/MCI
322 estimate age 67.8: NfL: ratio estimate = 1.359, 95% CI: (1.042, 1.772), p=0.0242; GFAP: ratio estimate =
323 0.945, 95% CI: (0.699, 1.278), p=0.7091), as expected from previous studies^{17,28}. Interestingly, the plasma
324 concentration of NfL showed age-associated higher levels in the participants with mild-to-moderate AD
325 (2.714% per year, 95% CI: (0.625%, 4.847%), p=0.0122) (**Figure 5A**), whereas GFAP plasma

326 concentrations did not show age-associated higher levels in the participants with mild-to-moderate AD (-
327 0.030% per year, 95% CI: (-2.061%, 2.042%), p=0.9761). Plasma concentrations of both NfL and GFAP
328 showed age-associated higher levels for MCI (NfL: 4.138% per year, 95% CI: (1.664%, 6.672%), p=0.0017;
329 GFAP: 3.466% per year, 95% CI: (0.170%, 6.871%), p=0.0398) (**Figure 5B**). There were no statistically
330 significant differences among the age slopes for healthy controls, AD, and MCI for either NfL or GFAP.


331

332 UCH-L1 levels in the participants with MCI due to AD are higher overall than the plasma UCH-L1
333 concentrations of the healthy control participants at the mean age for the sargramostim/GM-CSF-treated
334 mild-to-moderate AD participants, 67.8 years (ratio estimate = 1.440, 95% CI: (1.101, 1.885), p=0.0088),
335 whereas the plasma UCH-L1 concentrations of the mild-to-moderate AD participants at the baseline visit
336 prior to GM-CSF/sargramostim treatment are approximately the same as those of the healthy control
337 participants (ratio estimate = 0.967, 95% CI: (0.798, 1.171), p = 0.7257) (**Figure 5C**). UCH-L1
338 concentrations in MCI were higher than in mild-to-moderate AD at 67.8 years (ratio estimate = 1.490, 95%
339 CI: (1.133, 1.961), p=0.0052). UCH-L1 increased for participants with mild-to-moderate AD by an estimated
340 2.420% per year of age (95% CI: (0.783%, 4.083%), p=0.0054), while the estimated age-associated increase
341 for MCI is marginally statistically non-significant (estimate = 2.499% per year, 95% CI: (-0.446%, 5.531),
342 p=0.0941), possibly because it is underpowered with the modest sample size. There were no statistically
343 significant differences among the age slopes for healthy controls, mild-to-moderate AD, and MCI for UCH-
344 L1 (interaction test p value = 0.2040). This analysis suggests that during the age-associated progression to
345 mild-to-moderate AD, plasma levels of GFAP and NfL, markers of astrogliosis and axonal damage,
346 respectively, rise with the level of cognitive decline, but UCH-L1 measures of neuronal cell damage are
347 higher early during the MCI phase and are then closer to normal at the mild-to-moderate AD stage, perhaps
348 due to lower neuronal loss, or to lower release of UCH-L1 from neurons.

349
350
351

352
353

Figure 5.



354

C

354

375 **Figure 5. Comparisons between plasma NfL, GFAP, and UCH-L1 concentrations and age in**
376 **participants with MCI due to AD, participants with mild-to-moderate AD, and healthy control**
377 **participants.**

378 We compared the concentrations of NfL, GFAP, and UCH-L1 in plasma samples from participants assessed
379 as having MCI due to AD as part of the CUACC Bio-AD longitudinal observational study (n=32) (MCI), and
380 36 participants from the Phase II, double-blind, randomized, placebo-controlled trial with recombinant
381 human GM-CSF (the “sargramostim/GM-CSF AD trial”) at baseline prior to treatment with
382 sargramostim/GM-CSF or placebo (Baseline AD GM-CSF Study Pooled), and the corresponding segment of

383 the age curve from the 317 healthy control participants who were part of either the Crnic Institute Human
384 Trisome Project (HTP) (n=103), the CUACC Bio-AD longitudinal observational study (n=69), or the MS
385 healthy controls biomarker study (n=145). The mean age for the sargramostim/GM-CSF-treated mild-to-
386 moderate AD participants was 67.8 years.

387 **(A)** Plasma NfL concentrations in participants with MCI or mild-to-moderate AD are higher, correlating with
388 disease progression, than in age-matched healthy control participants and also show an increase with age
389 (MCI geometric mean estimate 15.27 pg/ml (95% CI: (12.54, 18.58) pg/ml) at age 67.8; mild-to-moderate
390 AD geometric mean estimate of 20.75 pg/ml (95% CI: (17.22, 25.01) pg/ml) at age 67.8 and baseline
391 calibrated compared to age-matched healthy control participants (geometric mean estimate of 11.21 pg/ml
392 (95% CI: 10.36, 12.13) pg/ml; MCI/HC ratio estimate = 1.362, 95% CI: (1.104, 1.682), p=0.0050; AD/HC
393 ratio estimate = 1.852, 95% CI: (1.514, 2.265), p = 2.201 * 10⁽⁻⁷⁾). NfL was statistically significantly
394 higher in AD than in MCI at 67.8 years (ratio estimate = 1.359, 95% CI: (1.042, 1.772), p=0.0242). The
395 estimated exponential change in plasma NfL for MCI was 4.138% per year (95% CI: (1.664%, 6.672%),
396 p=0.0017) and for mild-to-moderate AD was 2.714% per year (95% CI: (0.625%, 4.847%), p = 0.0122). The
397 differences between the MCI or mild-to-moderate AD rate of change and healthy control rate of change were
398 not statistically significant for NfL, but the power of the comparison test is limited because of the small
399 sample size of the mild-to-moderate AD group (interaction test p value = 0.3953).

400 **(B)** Participants with MCI or mild-to-moderate AD exhibit a higher concentration of plasma GFAP (MCI:
401 geometric mean estimate = 191.78 pg/ml, 95% CI: (147.18, 249.89) pg/ml) (AD: geometric mean estimate of
402 181.28 pg/ml (95% CI: (155.40, 211.46) pg/ml) at the sargramostim/GM-CSF mean age of 67.8 and baseline
403 calibrated) compared to age-matched healthy control participants (geometric mean estimate of 98.43 pg/ml
404 (95% CI: (89.51, 108.24) pg/mL; MCI/HC ratio estimate = 1.948, 95% CI: (1.473, 2.577), p = 2.230 * 10⁽⁻⁵⁾);
405 AD/HC ratio estimate = 1.842, 95% CI: (1.539, 2.203), p = 4.169 * 10⁽⁻⁹⁾). GFAP levels for mild-to-
406 moderate AD and MCI were similar at 67.8 years (AD/MCI ratio estimate = 0.945, 95% CI: (0.699, 1.278),
407 p=0.7091). The levels for the MCI participants increase with age (estimated change per year = 3.466%, 95%
408 CI: (0.170%, 6.871%), p=0.0398), but the levels do not change for the mild-to-moderate AD participants
409 (estimated change per year = -0.030%, 95% CI: (-2.061%, 2.042%), p = 0.9761). The differences between
410 the MCI or AD rate of change and healthy control rate of change were not statistically significant for GFAP,
411 but the power of the comparison test is limited because of the small sample size of the mild-to-moderate AD
412 group (interaction test p value = 0.1482).

413 **(C)** The mean of plasma UCH-L1 concentrations in participants with MCI due to AD is statistically
414 significantly higher (ratio estimate = 1.440, 95% CI: (1.101, 1.885), p=0.0088, at mean age of 67.8 years)
415 than for healthy control participants, indicating the initiation of neurodegeneration beyond that caused by
416 normal aging alone. Notably, the mean plasma concentrations of UCH-L1 at baseline for mild-to-moderate
417 AD participants in the sargramostim/GM-CSF AD trial are similar to the concentrations in the healthy
418 control participants at the corresponding age (ratio estimate = 0.967, 95%: (0.798, 1.171), p = 0.7257),
419 possibly because neuronal loss has reduced the numbers of neurons available to release UCH-L1, but the
420 increase with age remains statistically significant (estimated change per year = 2.420%, 95% CI: (0.783%,
421 4.083%), p=0.0054). The estimated slopes of the association between plasma UCH-L1 concentrations and
422 age in the participants with MCI due to AD (estimated change per year=2.499%, 95% CI: (-0.446%,
423 5.531%), p = 0.0941) or with mild-to-moderate AD are between 2 to 2.5, which is the slope of the correlation
424 between plasma UCH-L1 concentrations and age in the healthy control participants in Figure 1 (estimated
425 change per year=1.110%, 95% CI: (0.716%, 1.505%), p = 5.504 * 10⁽⁻⁸⁾), but the differences are not
426 statistically significant, most likely due to the small numbers of participants in the MCI due to AD group and
427 in the mild-to-moderate AD group (interaction test p value = 0.2040).

428

429

430 **Treatment of AD trial participants with sargramostim/GM-CSF reverses the rate of neuronal loss to**
431 **that of normal controls many decades younger.**


432 In addition to identifying potential mechanisms of brain aging, age-associated biomarkers may be used to
433 assess the efficacy of interventions that may slow or even halt the aging process. We have previously
434 discovered GM-CSF/sargramostim as a potential treatment for AD whose likely mechanisms of action may
435 include targeting the aging process in the brain. Specifically, based on early studies showing that RA patients
436 had a reduced risk of developing AD, we hypothesized that this protection might be due to a physiological
437 reaction against RA's associated inflammation, with the beneficial side effect of reducing the risk of AD,
438 which exhibits brain inflammation. We tested our hypothesis and found that treatment of a mouse model of
439 AD with GM-CSF, an immune system stimulating/modulating cytokine that stimulates the proliferation of
440 immune stem cells in both the bone marrow and the brain and is upregulated in the plasma of RA patients,
441 reduced brain amyloid levels by half, increased brain synaptophysin levels, and restored memory to normal
442 after a few weeks of subcutaneous administration³⁵. This finding was subsequently confirmed in a different
443 mouse model of AD³⁶. Furthermore, we and others have shown that GM-CSF treatment also improves
444 cognition and neuronal function in aged wild-type mice, indicating that the beneficial effects of GM-CSF on
445 the brain are not exclusively targeting AD pathology but also extend to normal aging^{35,37,38}.

446
447 Building on this foundation, we recently completed a Phase II, double-blind, randomized, placebo-controlled
448 trial of human recombinant GM-CSF (sargramostim) (250 mcg/m²/day subcutaneous injection, five
449 days/week for three weeks) in participants with mild-to-moderate AD³³. Treatment with sargramostim led to
450 improved scores in the Mini-Mental State Exam (MMSE) by almost two points (compared to baseline and to
451 placebo) and moved the concentrations of AD-associated plasma biomarkers—amyloid, total Tau—toward
452 normal. This was the first full phase II trial of an intervention that showed improvement, instead of slowing,
453 in AD patients³³. Interestingly, the largest change in a measure of AD neuropathology at the end of
454 treatment was in plasma UCH-L1 concentrations, which had decreased in the sargramostim-treated group by

455 40% compared to baseline ($p=0.0017$) and by 42% compared to placebo ($p=0.0019$)³³. However, in that
456 study we had no way to assess the true impact of the reduction of plasma UCH-L1 concentrations compared
457 to cognitively normal individuals. Here, we therefore compared the previous results to the age curves for
458 UCH-L1 shown in **Figure 1** to determine how effective sargramostim/GM-CSF treatment was in reducing
459 this measure of neuronal loss with aging.

460

461 The plasma concentrations of UCH-L1 in mild-to-moderate AD participants at baseline and at the end of
462 treatment with sargramostim/GM-CSF are plotted with the data from healthy control participants in **Figure**
463 **6A** and show that the absolute values of plasma UCH-L1 are greatly reduced after sargramostim/GM-CSF
464 treatment (ratio estimate = 0.497, $p=0.0008$). Indeed, sargramostim/GM-CSF treatment reduces the
465 concentrations of UCH-L1 in plasma of trial participants to an average level far below those of similarly
466 aged healthy control participants (ratio estimate = 0.502, $p=0.0019$), and equivalent to that found in healthy
467 control participants six decades younger (**Figure 6A**). For example, a 67.8-year-old mild-to-moderate AD
468 participant treated with sargramostim/GM-CSF would have had a plasma UCH-L1 concentration of 6.47
469 pg/ml (geometric mean, 95% CI: (4.45, 9.39) pg/ml, not baseline calibrated – sargramostim/GM-CSF
470 baseline only), which is equivalent to that expected of a 5.4-year-old healthy control participant, based on our
471 cross-sectional data. This conclusion required the comparison of the plasma UCH-L1 data from the
472 sargramostim treatment trial to the new data shown in **Figure 1**. The rate of loss of UCH-L1-positive
473 neurons during sargramostim/GM-CSF treatment in the clinical trial is shown in **Figure 6B**: the three-week
474 treatment resulted in a reduction in the rate of UCH-L1 neuron deaths by 2.62 million neuron deaths per year
475 per person (95% CI: (1.53, 3.71) million).



477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503


504

Figure 6. Treatment of participants with mild-to-moderate AD with sargramostim/GM-CSF reduces plasma UCH-L1 concentrations and neuronal loss to levels seen in healthy control participants six and a half decades younger with an average comparable to that of 5.2-year-old healthy control participants.

Association plots and point wise standard errors are shown for the participants with mild-to-moderate AD from the Phase II, double-blind, randomized, placebo-controlled trial with recombinant human GM-CSF (the “sargramostim/GM-CSF AD trial”) at baseline before they were treated with sargramostim/GM-CSF (AD Untreated - GM-CSF Baseline, n=18) or after they were treated with sargramostim/GM-CSF (AD GM-CSF Treatment, n=18) together with the correlation curve for healthy control participants from Figure 1 (A). The comparison shows that treatment of participants with mild-to-moderate AD with sargramostim/GM-CSF leads to absolute UCH-L1 values that are greatly reduced compared to their starting (baseline) levels (ratio estimate = 0.497, 95% CI: (0.350, 0.705), p=0.0008). Furthermore, sargramostim/GM-CSF treatment reduces expected plasma UCH-L1 concentrations far below those of similarly aged healthy control participants (ratio estimate = 0.502, 95% CI: (0.341, 0.741), p=0.0019 at a mean age of 67.8 years), and leads to a geometric average plasma UCH-L1 level that sets a 67.8-year-old mild-to-moderate AD participant approximately equal to that expected of a 5.4-year-old healthy control participant (horizontal dotted line). The healthy control age equivalent of the plasma concentrations of UCH-L1 after GM-CSF treatment ranged from around 4 years old for 67-year-old mild-to-moderate AD participants to around 32 years old for 80-year-old mild-to-moderate AD participants. The reduced plasma UCH-L1 levels associated with GM-CSF-treatment of mild-to-moderate AD participants are statistically significantly lower than those of all healthy control participants above approximately age 37.8 (vertical dot-dash line) but are statistically indistinguishable (p>0.05) from healthy control participants younger than age 37.8. The plots calculated for neuron loss are shown in (B), which indicate that this three-week treatment resulted in a reduction in the rate of neuron deaths by 2.62 million neuron deaths per year per person (95% CI: (1.53, 3.71) million).

505 **GM-CSF treatment reverses neuronal apoptosis in hippocampi of AD rats.** To investigate the
506 mechanism by which GM-CSF treatment reduces plasma concentrations of UCH-L1 and thus neuronal
507 death, we examined aged TgF344-AD rats (18-20 months of age), a model of AD that shows the complete
508 brain pathology of human AD (amyloid and Tau deposition and neuronal loss)³⁹. TgF344-AD rats were
509 treated with recombinant rat GM-CSF or saline placebo for five weeks, and their brains were assessed by
510 immunohistochemical staining for Caspase-3, a marker of apoptosis that is increased in humans and animal
511 models with AD, and during aging^{40,41}. Data from the treated TgF344-AD rats were also compared to age-
512 matched wild-type (WT) control F344 rats. As shown in **Figure 7**, aged TgF344-AD rats treated with saline
513 exhibited large numbers of Caspase-3-positive cells in the CA1, CA3, and dentate gyrus/hilus regions of the
514 hippocampus compared to WT F344 rats. GM-CSF treatment of aged TgF344-AD rats significantly reduced
515 the elevated number of Caspase-3-positive cells compared to placebo-treated TgF344-AD rats, almost
516 reaching the low number observed in the untreated WT F344 rats. Notably, the vast majority of Caspase-3-
517 positive cells in the TgF344-AD rats were neurons (approximately 95%) based on co-staining for the MAP2
518 neuronal marker (data not shown). These results indicate that the statistically significant reduction in plasma
519 UCH-L1 in the sargramostim/GM-CSF-treated human AD participants is likely reflecting the biologically
520 significant prevention of AD-associated neuronal apoptosis.

521
522



564 **Figure 7. Treatment with GM-CSF reduces neurodegeneration and neuronal cell death in a rat model**
 565 **of AD.**

566 Aged male TgF344-AD rats (18-20 months), a model of AD that overexpresses human A β peptide³⁹, were
 567 treated with GM-CSF or placebo for five weeks as described, and the levels of neuronal damage were
 568 assessed by immunohistochemical staining for Caspase-3 (red) together with DAPI staining (blue), followed
 569 by blinded counting of Caspase-3-positive cells. Arrowheads in the inserts indicate Caspase-3-positive cells.
 570 The numbers of Caspase-3-positive cells were determined in the CA1 (A-C), the CA3 (D-F), and the dentate
 571 gyrus/hilus (G-I) regions of the hippocampus in age-matched F344 male wild-type (WT) rats (A,D,G),
 572 TgF344-AD rats injected with saline at the end of treatment (B,E,H), and TgF344-AD rats treated with GM-

573 CSF at the end of treatment (C,F,I). Quantitative analyses showed a significantly higher number of Caspase-
574 3-positive cells in all three regions of TgF344-AD rats injected with saline compared to age-matched WT rats
575 (p values as indicated), which decreased significantly with GM-CSF treatment (p values as indicated; J-L).
576 For each bar, data are represented as mean +/- SEM for separate groups of mice. Statistical significance was
577 determined by the unpaired Student's *t*-test for comparison between groups. Scale bar: 100 μ m (20X
578 magnification). All experiments were repeated 2-6 times with similar results (n=5 for WT rats, n=7 for
579 Tg344-AD rats injected with saline, and n=7 for Tg344-AD rats treated with GM-CSF). Notably, the vast
580 majority of Caspase-3-positive cells in the analyzed regions in the TgF344-AD rats were neurons
581 (approximately 95%) as determined by co-staining for the MAP2 neuronal marker (data not shown).
582

583

584 Discussion

585

586 The identification of biomarkers of brain aging is an area of active investigation, and our study has important
587 strengths over previous reports. For example, the identification of biomarkers of aging in different organs,
588 including brain, has been reported recently²⁰. However, that study examined a limited age spectrum and thus
589 does not give insights into when brain aging begins, as we have found. Furthermore, the 'cognition brain'
590 markers examined in that study related more to neuronal function than to neuronal loss or damage per se.
591 Most importantly, previous studies have not shown an **exponential** age-associated elevation in markers of
592 brain damage across the life span that our data show.

593

594 An exponential increase in any product of a biological process implies the existence of at least one positive
595 feedback loop that accelerates the process. Our finding of exponential rises in the cross-sectionally assessed
596 markers of brain degeneration, first of neuron loss and axon damage, and then of
597 astrogliosis/neuroinflammation with age and their strong correlations with each other evidenced in **Figures**
598 **1-4** implies the existence of such a positive feedback loop in the process of brain aging. Specifically, the rise
599 in neuron loss and axon damage evident in plasma from early childhood is likely to induce
600 gliosis/inflammation to phagocytose the resulting debris, which would initiate the 'inflammaging' cascade,
601 resulting in a vicious cycle of more neuronal damage and death and more inflammation.

602 Notably, the positive feedback loop involving neuronal loss/damage and inflammation in brain aging
603 throughout life that the new data demand includes the same components as the already-established positive

604 feedback loop that comes into play later, in the development of AD. Specifically, we and others have found
605 that gliosis/neuroinflammation in AD increases the expression of cytokines that lead through several steps to
606 increased production of A β peptides and their polymerization into neurotoxic oligomers and filaments. The
607 resulting A β oligomers, in turn, further increase neuroinflammation through further activation of microglia
608 and astrocytes^{15,16,42-44}. Such positive feedback loops are ideal targets for developing inhibitors of pathogenic
609 pathways. The other key discovery of our investigation here—that a long-approved immune stem cell
610 stimulating drug, GM-CSF/sargramostim, can be repurposed to reverse age-associated neuronal loss in both
611 human research participants and an animal model of AD—illustrates the benefit of blocking a key step in the
612 feedback loop of age-associated brain degeneration.

613

614 In sum, our findings allow several novel conclusions to be drawn:

- 615 1. The concentrations of two plasma biomarkers of neuronal damage, UCH-L1 (**Figure 1**) and NfL
616 (**Figure 2**), are exponentially higher with increasing age in healthy control participants, indicating
617 that normal brain aging is a process that starts in early childhood, continues throughout life, and
618 becomes behaviorally apparent only later in life, probably as the neuronal damage overcomes
619 functional redundancy and resiliency.
- 620 2. The higher levels of neuron-derived UCH-L1 concentrations in plasma with age in healthy control
621 participants imply an exponential increase in the loss of, or severe damage to, neurons (estimated as a
622 loss of roughly several hundred million neurons over a lifespan, or a minimum of 338 million neuron
623 deaths per person in the sex pooled model (**Supplementary Figure 2**) and also provides an additional
624 ‘N’ measure for the AD ‘AT(N)’ assessment tool. Presumably, neurogenesis, which has also been
625 shown to occur throughout life, replaces some of the neurodegeneration⁴⁵. Neuronal loss may be
626 larger in specific brain regions, such as the hippocampus, which is relatively small and plays a key
627 role in learning and memory.

- 628 3. Based on cross-sectional data, the elevations in the concentrations of the plasma biomarkers of
629 neuronal damage, UCH-L1 and NfL, in healthy control participants occur earlier than the increase in
630 astrogliosis (GFAP), which accelerates significantly after age 40 (**Figure 3**), indicating that
631 astrogliosis and its attendant inflammation ('inflammaging') are likely to be both a response to, and
632 an accelerator of, the age-related neuronal damage, rather than an initiating cause. Indeed, this
633 acceleration is evidence of a positive feedback loop that explains the exponential feature of the age-
634 associated increase in all three biomarkers and of the age-associated risk of AD.
- 635 4. The higher levels in the measures of neuronal damage and reactive astrogliosis that coincide with
636 increasing age in healthy control participants are highly correlated with each other and may underlie
637 the enhanced risk of developing AD and other neurodegenerative diseases with increased age (**Figure**
638 **4**).
- 639 5. Because plasma concentrations of NfL (**Figure 5A**) and GFAP (**Figure 5B**) are higher in participants
640 with MCI and mild-to-moderate AD compared to healthy control participants, they appear to reflect
641 active AD-associated injury, with NfL levels being higher after the MCI to AD progression. In
642 contrast, plasma concentrations of UCH-L1 were higher in participants with MCI than in healthy
643 control participants or participants with mild-to-moderate AD (**Figure 5C**), which may reflect greater
644 leakage from damaged neuronal cell bodies early in the disease process compared to healthy aging
645 brains.
- 646 6. The higher age-associated levels in plasma concentrations of UCH-L1 as a measure of greater
647 neuronal cell loss in females (**Figure 1C and 1D**) should be further explored to clarify whether this
648 explains or contributes to their increased risk for age-associated neurodegenerative diseases such as
649 AD.
- 650 7. Although the standard errors of the mean for the concentration versus age curves for all three
651 biomarkers are very tight across the lifespan, there is variance between individuals. Such variance

652 may reflect increased risk or resilience to the development of AD or AACD caused by genetic
653 variants such as *APOE4* alleles⁴³, lifestyle, environment, or other as-yet unidentified factors¹⁰.
654 8. Higher plasma concentrations of UCH-L1 in an individual compared to the expected age-associated
655 level of the healthy control participant curve may serve as a predictive biomarker for the future
656 development or onset of MCI (**Figure 5C**).

657

658 Traditional treatments for AD (e.g., cholinesterase inhibitors and memantine) provide only marginal short-
659 term benefits by improving acetylcholine neuronal transmission or modulating excitotoxicity, but they do not
660 modify or target the disease mechanism. The recently FDA-approved anti-A β /amyloid monoclonal
661 antibodies, aducanumab, lecanemab, and donanemab remove amyloid deposits effectively in clinical trials,
662 but they may only slow progressive cognitive decline and can lead to amyloid-related imaging abnormalities
663 (ARIAs; brain edema and micro-hemorrhages) and have been linked with smaller brain volumes^{46,47}.
664 Because most current approaches to AD therapy target AD pathologies in symptomatic adults, none are
665 designed or expected to address the contribution of aging to the development of AD.

666

667 In contrast to other potential treatments for AD, sargramostim/GM-CSF is also beneficial in normal AACD
668 mouse models and for many neurological injuries and diseases without associated AD pathology, for
669 example in animal models of stroke, TBI, and Parkinson's disease⁴⁸⁻⁵¹, in humans with chemobrain⁵², and in
670 a preliminary clinical trial in participants with Parkinson's disease⁵³. Its broad therapeutic applicability may
671 be related to the ability of GM-CSF to cross the blood-brain barrier, to be both neuroprotective and anti-
672 apoptotic, to stimulate arteriogenesis and blood flow, to promote axon preservation/regeneration and
673 neuronal plasticity, and to induce the proliferation of neural stem cells^{51,54-58} (for more references and
674 discussion see¹⁶). The finding that sargramostim/GM-CSF treatment in participants with mild-to-moderate
675 AD in the completed Phase II trial led to reduced plasma concentrations of UCH-L1, but not of NfL or
676 GFAP, may be due to the very short treatment period of three weeks. In TBI, plasma UCH-L1 levels increase

677 very rapidly, which dynamically reflects neuronal damage, and then return quickly to baseline after the insult
678 ends, whereas NfL and GFAP are long-lived biomarkers that increase more slowly but persist with longer
679 half-lives and would thus be expected to take longer to show a decrease in response to AD interventions such
680 as sargramostim/GM-CSF⁵⁹. Our current NIH-funded trial of longer-term treatment (six months) with
681 sargramostim/GM-CSF in participants with mild-to-moderate AD (NCT04902703) may reveal a reduction in
682 plasma concentrations of NfL and GFAP later during the treatment period.

683

684 The finding that three weeks of sargramostim/GM-CSF treatment of participants with mild-to-moderate AD
685 in a Phase II, double-blind, randomized, placebo-controlled trial led to improved performance on a cognitive
686 measure (almost 2 points on MMSE) and changes in plasma levels of markers of AD neuropathology (A β 40,
687 total Tau, and UCH-L1)³³, together with the novel findings reported here, allow the following additional and
688 novel conclusions to be drawn:

689

690 9. Sargramostim/GM-CSF treatment of participants with mild-to-moderate AD and rats that model AD
691 effectively halts neuronal cell loss assessed by the plasma concentration of UCH-L1 (**Figure 6**) or
692 Caspase-3/apoptosis (**Figure 7**), respectively.

693 10. Because a reduction in plasma UCH-L1 was a measure of successful treatment of AD participants
694 with sargramostim/GM-CSF (³³ and **Figure 6**), UCH-L1 measures may be a sensitive biomarker for
695 testing the efficacy of other AD treatments and therapeutic changes in lifestyle.

696

697 Our finding that GM-CSF treatment significantly reduced the elevated apoptosis in the CA1, CA3, and
698 dentate gyrus/hilus regions of the hippocampus in the TgF344-AD rat model of AD to levels that were close
699 to those of age-matched WT control rats (**Figure 7**) suggest that the ability of GM-CSF to improve cognition
700 as measured by MMSE, to partially normalize the concentrations of amyloid and tau plasma biomarkers, and
701 to greatly reduce the plasma concentrations of the biomarker of neurodegeneration, UCH-L1, in our

702 previously published Phase II clinical trial of participants with mild-to-moderate AD ³³ is likely due to a
703 reduction in the number of apoptotic cells in the brain. This reduction in apoptosis is likely due in part to
704 suppression of apoptosis itself, which GM-CSF has been shown to effect, which would thus increase total
705 levels of UCH-L1 and its synaptic function in the larger number of remaining neurons ^{31,56,57}. Furthermore,
706 we and others have found that apoptotic/damaged brain neurons in neurodegenerative diseases, including
707 AD, are often aneuploid, which would lead to substantial changes in gene expression and defects in cellular
708 functions, and that aneuploidy also leads to apoptosis (for review see ⁶⁰). Indeed, cells naturally undergoing
709 senescence accumulate with increased age, and their removal with ‘senolytic’ molecules can reverse some
710 features of aging, including improving cognition in animal models of AD ^{42,61-63}. Similarly, through its ability
711 to stimulate the production and activity of innate immune phagocytes (i.e., microglia) in the brain, GM-CSF
712 treatment may enhance the removal of damaged, apoptotic, senescent neurons, just as it caused the rapid
713 reduction of neurotoxic amyloid deposits in the brains of GM-CSF-treated AD mice ³⁵ and AD rats
714 (manuscript in preparation), thus allowing the remaining neurons to function more effectively. In sum, our
715 mechanistic studies in TgF344-AD rats are consistent with the conclusion that:

716

717 11. GM-CSF treatment has an anti-apoptotic function and possibly a senolytic function that reduces the
718 number of abnormal neurons and thus reverses neuronal defects and cognitive decline due to
719 neurodegenerative disease or aging.

720

721 In participants with mild-to-moderate AD, the benefits of GM-CSF treatment in improving cognition and
722 reducing plasma markers of neuropathology, including plasma concentrations of UCH-L1, is evidently
723 temporary. The disease is ongoing and all markers of neuropathology return to almost pre-treatment levels by
724 45 days after sargramostim/GM-CSF treatment is halted; yet there is still a statistically significant benefit to
725 cognition as measured by MMSE at 45 days post-treatment compared to the placebo ³³. It remains to be
726 determined whether treatment of healthy aged individuals with sargramostim/GM-CSF will reduce age-

727 associated neuronal damage and reverse AACD only with continuous application or whether it may similarly
728 confer a more long-lived benefit after treatment is halted.

729

730 Limitations:

- 731 a) Patients with MCI and dementia due to AD were identified by clinical diagnosis, not confirmed with
732 CSF markers or PET. There were no cutoffs used. Thus, we could not categorize participants into
733 A/T/N positivity. Although plasma AD biomarkers are increasingly used, future studies to confirm
734 our findings would benefit from an analysis of CSF samples or from the use of mass spectrometry to
735 analyze plasma biomarkers.
- 736 b) Pooled data were obtained from cross-sectional/baseline assessments from different studies with
737 different inclusion/exclusion criteria, which is also a strength. Caution is warranted in interpreting
738 longitudinal *change* in outcomes, as we cannot rule out cohort effects and resulting bias. Future
739 studies should assess these biomarkers longitudinally across the lifespan, and/or pool studies with
740 harmonized recruitment/enrollment techniques to confirm the results.
- 741 c) High CVs in UCHL-1 measures may impact the clinical application of these findings, with cutoffs.

742

743 **Methods**

744 **Experimental Design**

745 **Participants:** All human subjects research was approved by the Colorado Multiple Institutional Review
746 Board (COMIRB). Specifically, we analyzed healthy control plasma samples from three different studies.
747 Healthy control participants (n=317) who were part of the Crnic Institute Human Trisome Project (HTP,
748 n=103; age range: 2-61 years; 54% female) (COMIRB #15-2170; NCT0284108; Dr. Espinosa), the
749 University of Colorado Alzheimer's and Cognition Center (CUACC) Bio-AD longitudinal observational
750 study (n=69; age range: 53-83; 70% female) (COMIRB #15-1774; Dr. Bettcher), or the multiple sclerosis
751 (MS) healthy controls biomarker study (termed Nair) (n=145; age range: 16-86; 64% female; 3 participants
752 lacked usable UCH-L1 data) (COMIRB #21-3703; Dr. Nair). See demographics in **Supplementary Table 1**.
753 The HTP is focused on studying biomarkers and clinical features of people with Down syndrome (DS) and
754 includes typical control participants without DS⁶⁴, and the CUACC Bio-AD study is focused on studying the
755 effect of inflammation on the development of AD¹⁷. The Nair MS biomarker study is investigating
756 biomarkers associated with MS and includes healthy control participants. Together, these three healthy
757 control cohorts span ages 2-85.

758

759 Using three community-dwelling healthy control cohorts that are diverse and heterogenous with a wide range
760 of ages adds confidence to the cross-sectional measures of the plasma biomarkers. If different
761 populations had different levels and slopes of a marker with age, then pooling them would be averaging them
762 and would cause a deviation away from linearity across the full age range, with parametric linear fit trying to
763 smooth it out. However, there is no appreciable deviation from linearity for UCH-L1 or NfL when examined
764 with the spline fits⁶⁵ (**Supplementary Figure 1**). GFAP measures across age are more complex, increasing
765 exponentially only after age 40.

766

767 Participants assessed as having mild cognitive impairment (MCI) due to AD (n=32) were part of the CUACC
768 Bio-AD longitudinal observational study and were diagnosed based on an interdisciplinary consensus
769 conference with review of cognitive testing, neurological examination, clinical dementia rating scale (CDR),
770 and brain MRI (COMIRB# 15-1774; Dr Bettcher). Participants with mild-to-moderate AD were from our
771 published Phase II, double-blind, randomized, placebo-controlled trial³³ with recombinant human GM-CSF
772 (the “sargramostim/GM-CSF AD trial”) (COMIRB # 12-1273; NCT 01409915). We include available
773 plasma samples taken at the baseline visit prior to treatment with sargramostim/GM-CSF or placebo (n=36),
774 as well as available plasma samples taken at the end of three weeks of treatment with either GM-CSF (n=18)
775 or placebo (n=18). Some plasma samples were unavailable for measurements of NfL and GFAP
776 concentrations.

777

778 **Measurement of plasma biomarker concentrations:** Concentrations of UCH-L1, GFAP, and NfL in
779 plasma samples were assessed in healthy control participants and in participants with MCI due to AD using
780 published methods^{17,33} and the Quanterix single molecule array, or SIMOA[®], SR-X Analyzer system and the
781 Neuro-4-Plex B kits. Concentrations of UCH-L1, GFAP, and NfL in the samples from mild-to-moderate AD
782 participants in the sargramostim/GM-CSF AD trial were determined in our previously published manuscript
783 using the same methods³³.

784

785 **Rat AD model:** Animal research was approved by the University of Colorado Institutional Animal Care and
786 Use Committee (IACUC#00878). The TgF344-AD rat was developed as a model of AD by inserting
787 transgenes that express the Swedish mutant human *APP* (*APP^{sw}*) and mutant human presenilin 1 (*PSEN1*
788 *delta E9*) genes that cause familial AD³⁹. As a result, and due to the fact that the rat MAPT (Tau) gene
789 resembles the human version, the TgF344-AD rats overexpress human A β peptide and develop the full
790 complement of human AD brain pathology: amyloid deposits, p-Tau-positive neurofibrillary tangles, and
791 neuronal loss. Untreated age-matched wild-type (WT) F344 rats were used as controls. The 18- to 20-month-

792 old TgF344-AD male rats were injected subcutaneously with GM-CSF (83.3 mg/kg/day; 5 days/week; n=7)
793 or with saline (200 ml/day; 5 days/week; n=7) for 24 injections total over 32 days. On day 32, the rats were
794 anesthetized with sodium pentobarbital, perfused intracardially with PBS for 5-7 min, and the brains were
795 removed rapidly. The right hemisphere was immersed in freshly prepared 4% paraformaldehyde (PFA) in
796 PBS for 24 h at 4 °C. After fixing with PFA, 4 mm-thick paraffin-embedded hippocampal brain sections were
797 mounted on glass slides and processed for immunohistochemistry for the apoptosis marker Caspase-3 (Cell
798 signaling Technology; Cat# 9662) and stained with DAPI. A detailed protocol for immunohistochemistry and
799 imaging is described in ³⁸. We visually counted the numbers of Caspase-3-positive cells in the CA1, CA3,
800 and dentate gyrus/Hilus regions of the hippocampus (blinded as to genotype and treatment).

801

802 **Neuronal death calculation:** UCH-L1 is primarily a neuronal protein that is released from damaged neurons
803 in the brain, enters the CSF, and is ultimately released into the blood. Therefore, for each research
804 participant, it is possible to calculate the number of neurons that have released UCH-L1 in a given time
805 period based on the steady state concentration of plasma UCH-L1 ('C' in pg/ml from the individual
806 participant data of **Figure 1**), the half-life of UCH-L1 (estimated to be approximately 8.5 hours ^{66,67}), the
807 volume of plasma in a typical adult person (3,500 ml), and the amount of UCH-L1 per neuron (2.5% of total
808 protein (250 pg) ^{25,26} = 6.25 pg). Specifically, for each participant, the approximate number of neurons lost
809 per year can be calculated using the following formula:

810


811
$$\text{Number of Neurons Lost Each Year} = (C \text{ (pg/ml)} \times \ln 2 \times 3,500 \text{ ml}) / (8.5 \text{ h} \times 6.25 \text{ pg/neuron}) \times 24 \text{ h} \times 365 \text{ days}$$

812

813 **Statistical Analysis**

814 Data were analyzed using mixed model regression, with unstructured error covariance on repeated measures,
815 for the effects of biomarkers, disease status, and treatment on the logarithmic transforms of the plasma
816 biomarkers of UCH-L1, GFAP, and NfL. Although data from healthy control participants and participants

817 with MCI due to AD were cross-sectional, the framework of mixed model regression could still be adapted,
818 as regression with independent data is merely a simplified version of regression with correlated data. Healthy
819 control, MCI due to AD, mild-to-moderate AD at baseline, mild-to-moderate AD treated with placebo/saline,
820 and mild-to-moderate AD treated with sargramostim/GM-CSF were allowed different covariance matrices.
821 Because the biomarker data were measured using 2 or 3 replicates, all of the observations were used, instead
822 of averaging replicates and weighting. The age effects were modeled as log-linear, with separate age slopes
823 and intercepts for healthy control, MCI due to AD, and mild-to-moderate AD. The intercept for mild-to-
824 moderate AD depended on the treatment x study time, but a common age slope was assumed for all mild-to-
825 moderate AD participants, and independent of treatment effects. The log linearity assumption was checked
826 graphically, and by comparing to spline fits ⁶⁸. Interactions with sex were also considered. Linear
827 combinations of model parameters were estimated, along with 95% confidence intervals, back transformed,
828 and tested. Histograms of the Coefficient of Variation among replicates found some biomarker measures
829 obtained with the SIMOA[®], SR-X Analyzer system, particularly UCH-L1, for example, in analyses of the
830 effects of TBI, can have Coefficients of Variance much higher than 20%, indicating that the variance is an
831 inherent feature of the measure and not due, for example, to unreliable outliers. For example, a histogram of
832 the UCH-L1 coefficient of variance of the healthy controls is shown below:



833

834 There are known limitations to using biomarkers with high CVs in analyses, with most studies utilizing less
835 than 20% cutoffs at the higher end. The primary concern is that if analysis of the same sample twice yields
836 markedly different values, there are understandable concerns for reliability of measurement (and clinical
837 applicability). Variability of such measures limits their utility for assessing individuals from a small number
838 of replicates, but the laws of large numbers still allow us to estimate the average with a medium to large
839 sample. For cross-sectional comparisons between large cohorts, the average or log average of individual
840 participant's replicate measures is often used because measures of UCH-L1 often show high variance
841 ^{27,66,67,69}. UCH-L1 levels were FDA approved in 2018 as part of a measure of brain damage after TBI ⁷⁰.
842 Because some of our cohorts had two replicates for each participant (healthy controls and participants with
843 MCI due to AD from the Bio-AD) and some (healthy controls from the HTP, GM-CSF trial participants with
844 mild-to-moderate AD, and healthy controls from the MS study) had mostly three replicates for each
845 participant, and some of the biomarkers, especially UCH-L1, have high variability among replicates, we
846 decided in the modeling to use each replicate as a separate measure in the main analysis, rather than using the
847 averages of the individual participants' replicate measures. The variation among replicates was modeled by
848 introducing an additional noise term into the model. A common variance for the replicate noise term was
849 assumed across all treatments because of software option limitations. Model predicted values of the response,
850 along with pointwise standard errors, were plotted. All data calculations are provided in the **Supplementary**
851 **Tables 2-4**. As a test of confidence in the results, the averages of the participants' replicate measures for the
852 biomarkers were also modelled, weighted by the number of replicates, and the conclusions of age-associated
853 exponential increases in the three biomarkers, UCH-L1, NfL, and GFAP, and the effect of GM-CSF
854 treatment on reducing UCH-L1 levels were obtained. The overall results and conclusions were the same.
855 Univariate statistical significance was set at $\alpha = 0.05$, two-sided, for all tests unless otherwise stated.
856 Statistics were computed using SAS 9.4 and R 4.1.3. There are remaining limitations to using this approach
857 in terms of both within-site and cross-site replication of findings, and we acknowledge that it is challenging

858 to move a biomarker into clinical practice for AD with high CVs, although it has been done for UCH-L1 in

859 TBI.

860

861 **References**

- 862 1. Trollor, J.N., Smith, E., Agars, E., Kuan, S.A., Baune, B.T., Campbell, L., Samaras, K., Crawford, J.,
863 Lux, O., Kochan, N.A., et al. (2012). The association between systemic inflammation and cognitive
864 performance in the elderly: the Sydney Memory and Ageing Study. *Age (Dordr)* 34, 1295-1308.
865 10.1007/s11357-011-9301-x.
- 866 2. Singh, P.P., Demmitt, B.A., Nath, R.D., and Brunet, A. (2019). The Genetics of Aging: A Vertebrate
867 Perspective. *Cell* 177, 200-220. 10.1016/j.cell.2019.02.038.
- 868 3. Shcherbakov, D., Nigri, M., Akbergenov, R., Brilkova, M., Mantovani, M., Petit, P.I., Grimm, A.,
869 Karol, A.A., Teo, Y., Sanchón, A.C., et al. (2022). Premature aging in mice with error-prone protein
870 synthesis. *Sci Adv* 8, eab19051. 10.1126/sciadv.abl9051.
- 871 4. Potter, H. (1991). Review and hypothesis: Alzheimer disease and Down syndrome--chromosome 21
872 nondisjunction may underlie both disorders. *Am J Hum Genet* 48, 1192-1200.
- 873 5. Mattson, M.P., Longo, V.D., and Harvie, M. (2017). Impact of intermittent fasting on health and
874 disease processes. *Ageing Res Rev* 39, 46-58. 10.1016/j.arr.2016.10.005.
- 875 6. Maegawa, S., Lu, Y., Tahara, T., Lee, J.T., Madzo, J., Liang, S., Jelinek, J., Colman, R.J., and Issa, J.J.
876 (2017). Caloric restriction delays age-related methylation drift. *Nat Commun* 8, 539. 10.1038/s41467-
877 017-00607-3.
- 878 7. Lalli, M.A., Bettcher, B.M., Arcila, M.L., Garcia, G., Guzman, C., Madrigal, L., Ramirez, L., Acosta-
879 Uribe, J., Baena, A., Wojta, K.J., et al. (2015). Whole-genome sequencing suggests a chemokine gene
880 cluster that modifies age at onset in familial Alzheimer's disease. *Molecular psychiatry* 20, 1294-
881 1300. 10.1038/mp.2015.131.
- 882 8. Frasca, D., and Blomberg, B.B. (2016). Inflammaging decreases adaptive and innate immune
883 responses in mice and humans. *Biogerontology* 17, 7-19. 10.1007/s10522-015-9578-8.
- 884 9. Bettcher, B.M., Watson, C.L., Walsh, C.M., Lobach, I.V., Neuhaus, J., Miller, J.W., Green, R., Patel,
885 N., Dutt, S., Busovaca, E., et al. (2014). Interleukin-6, age, and corpus callosum integrity. *PloS one* 9,
886 e106521. 10.1371/journal.pone.0106521 [doi].
- 887 10. Boyle, P.A., Yu, L., Wilson, R.S., Leurgans, S.E., Schneider, J.A., and Bennett, D.A. (2018). Person-
888 specific contribution of neuropathologies to cognitive loss in old age. *Ann Neurol* 83, 74-83.
889 10.1002/ana.25123.
- 890 11. Risacher, S.L., Anderson, W.H., Charil, A., Castelluccio, P.F., Shcherbinin, S., Saykin, A.J., and
891 Schwarz, A.J. (2017). Alzheimer disease brain atrophy subtypes are associated with cognition and
892 rate of decline. *Neurology* 89, 2176-2186. 10.1212/wnl.0000000000004670.
- 893 12. Duara, R., Loewenstein, D.A., Potter, E., Appel, J., Greig, M.T., Urs, R., Shen, Q., Raj, A., Small, B.,
894 Barker, W., et al. (2008). Medial temporal lobe atrophy on MRI scans and the diagnosis of Alzheimer
895 disease. *Neurology* 71, 1986-1992. 10.1212/01.wnl.0000336925.79704.9f.
- 896 13. Hyman, B.T., Van Hoesen, G.W., Damasio, A.R., and Barnes, C.L. (1984). Alzheimer's disease: cell-
897 specific pathology isolates the hippocampal formation. *Science* 225, 1168-1170.
898 10.1126/science.6474172.
- 899 14. Alves, F., Kalinowski, P., and Ayton, S. (2023). Accelerated Brain Volume Loss Caused by Anti-β-
900 Amyloid Drugs: A Systematic Review and Meta-analysis. *Neurology* 100, e2114-e2124.
901 10.1212/wnl.0000000000207156.
- 902 15. Potter, H. (2001). *Beyond beta protein—the essential role of inflammation in Alzheimer Amyloid*
903 *formation* (Prominent Press).

- 904 16. Ahmed, M.M., Johnson, N.R., Boyd, T.D., Coughlan, C., Chial, H.J., and Potter, H. (2021). Innate
905 Immune System Activation and Neuroinflammation in Down Syndrome and Neurodegeneration:
906 Therapeutic Targets or Partners? *Front Aging Neurosci* *13*, 718426. 10.3389/fnagi.2021.718426.
- 907 17. Bettcher, B.M., Olson, K.E., Carlson, N.E., McConnell, B.V., Boyd, T., Adame, V., Solano, D.A.,
908 Anton, P., Markham, N., Thaker, A.A., et al. (2021). Astrogliosis and episodic memory in late life:
909 higher GFAP is related to worse memory and white matter microstructure in healthy aging and
910 Alzheimer's disease. *Neurobiol Aging* *103*, 68-77. 10.1016/j.neurobiolaging.2021.02.012.
- 911 18. McGeer, P.L., Schulzer, M., and McGeer, E.G. (1996). Arthritis and anti-inflammatory agents as
912 possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. *Neurology*
913 *47*, 425-432. 10.1212/wnl.47.2.425.
- 914 19. Zhou, M., Xu, R., Kaelber, D.C., and Gurney, M.E. (2020). Tumor Necrosis Factor (TNF) blocking
915 agents are associated with lower risk for Alzheimer's disease in patients with rheumatoid arthritis and
916 psoriasis. *PLoS One* *15*, e0229819. 10.1371/journal.pone.0229819.
- 917 20. Oh, H.S., Rutledge, J., Nachun, D., Pálovics, R., Abiose, O., Moran-Losada, P., Channappa, D., Urey,
918 D.Y., Kim, K., Sung, Y.J., et al. (2023). Organ aging signatures in the plasma proteome track health
919 and disease. *Nature* *624*, 164-172. 10.1038/s41586-023-06802-1.
- 920 21. Zecca, C., Pasculli, G., Tortelli, R., Dell'Abate, M.T., Capozzo, R., Barulli, M.R., Barone, R.,
921 Accogli, M., Arima, S., Pollice, A., et al. (2021). The Role of Age on Beta-Amyloid(1-42) Plasma
922 Levels in Healthy Subjects. *Front Aging Neurosci* *13*, 698571. 10.3389/fnagi.2021.698571.
- 923 22. Shir, D., Mielke, M.M., Hofrenning, E.I., Lesnick, T.G., Knopman, D.S., Petersen, R.C., Jack, C.R.,
924 Algeciras-Schimmich, A., Vemuri, P., and Graff-Radford, J. (2023). Associations of
925 Neurodegeneration Biomarkers in Cerebrospinal Fluid with Markers of Alzheimer's Disease and
926 Vascular Pathology. *J Alzheimers Dis* *92*, 887-898. 10.3233/jad-221015.
- 927 23. Morgan, A.R., Touchard, S., Leckey, C., O'Hagan, C., Nevado-Holgado, A.J., Barkhof, F., Bertram,
928 L., Blin, O., Bos, I., Dobricic, V., et al. (2019). Inflammatory biomarkers in Alzheimer's disease
929 plasma. *Alzheimers Dement* *15*, 776-787. 10.1016/j.jalz.2019.03.007.
- 930 24. Ohrfelt, A., Johansson, P., Wallin, A., Andreasson, U., Zetterberg, H., Blennow, K., and Svensson, J.
931 (2016). Increased Cerebrospinal Fluid Levels of Ubiquitin Carboxyl-Terminal Hydrolase L1 in
932 Patients with Alzheimer's Disease. *Dement Geriatr Cogn Dis Extra* *6*, 283-294. 10.1159/000447239.
- 933 25. Wang, K.K., Yang, Z., Sarkis, G., Torres, I., and Raghavan, V. (2017). Ubiquitin C-terminal
934 hydrolase-L1 (UCH-L1) as a therapeutic and diagnostic target in neurodegeneration, neurotrauma and
935 neuro-injuries. *Expert Opin Ther Targets* *21*, 627-638. 10.1080/14728222.2017.1321635.
- 936 26. Butterfield, D.A. (2021). Ubiquitin carboxyl-terminal hydrolase L-1 in brain: Focus on its
937 oxidative/nitrosative modification and role in brains of subjects with Alzheimer disease and mild
938 cognitive impairment. *Free Radic Biol Med* *177*, 278-286. 10.1016/j.freeradbiomed.2021.10.036.
- 939 27. Korley, F.K., Jain, S., Sun, X., Puccio, A.M., Yue, J.K., Gardner, R.C., Wang, K.K.W., Okonkwo,
940 D.O., Yuh, E.L., Mukherjee, P., et al. (2022). Prognostic value of day-of-injury plasma GFAP and
941 UCH-L1 concentrations for predicting functional recovery after traumatic brain injury in patients
942 from the US TRACK-TBI cohort: an observational cohort study. *Lancet Neurol* *21*, 803-813.
943 10.1016/s1474-4422(22)00256-3.
- 944 28. Graff-Radford, J., Mielke, M.M., Hofrenning, E.I., Kouri, N., Lesnick, T.G., Moloney, C.M.,
945 Rabinstein, A., Cabrera-Rodriguez, J.N., Rothberg, D.M., Przybelski, S.A., et al. (2022). Association
946 of plasma biomarkers of amyloid and neurodegeneration with cerebrovascular disease and
947 Alzheimer's disease. *Neurobiol Aging* *119*, 1-7. 10.1016/j.neurobiolaging.2022.07.006.
- 948 29. Brum, W.S., Ashton, N.J., Simrén, J., di Molfetta, G., Karikari, T.K., Benedet, A.L., Zimmer, E.R.,
949 Lantero-Rodriguez, J., Montoliu-Gaya, L., Jeromin, A., et al. (2023). Biological variation estimates of
950 Alzheimer's disease plasma biomarkers in healthy individuals. *Alzheimers Dement*.
951 10.1002/alz.13518.

- 952 30. Liu, H., Povysheva, N., Rose, M.E., Mi, Z., Banton, J.S., Li, W., Chen, F., Reay, D.P., Barrionuevo,
953 G., Zhang, F., and Graham, S.H. (2019). Role of UCHL1 in axonal injury and functional recovery
954 after cerebral ischemia. *Proc Natl Acad Sci U S A* *116*, 4643-4650. 10.1073/pnas.1821282116.
- 955 31. Smith, D.L., Pozueta, J., Gong, B., Arancio, O., and Shelanski, M. (2009). Reversal of long-term
956 dendritic spine alterations in Alzheimer disease models. *Proc Natl Acad Sci U S A* *106*, 16877-16882.
957 10.1073/pnas.0908706106.
- 958 32. Brum, W.S., Ashton, N.J., Simrén, J., di Molfetta, G., Karikari, T.K., Benedet, A.L., Zimmer, E.R.,
959 Lantero-Rodriguez, J., Montoliu-Gaya, L., Jeromin, A., et al. (2024). Biological variation estimates of
960 Alzheimer's disease plasma biomarkers in healthy individuals. *Alzheimers Dement* *20*, 1284-1297.
961 10.1002/alz.13518.
- 962 33. Potter, H., Woodcock, J.H., Boyd, T.D., Coughlan, C.M., O'Shaughnessy, J.R., Borges, M.T., Thaker,
963 A.A., Raj, B.A., Adamszuk, K., Scott, D., et al. (2021). Safety and efficacy of sargramostim (GM-
964 CSF) in the treatment of Alzheimer's disease. *Alzheimers Dement (N Y)* *7*, e12158.
965 10.1002/trc2.12158.
- 966 34. Kashon, M.L., Ross, G.W., O'Callaghan, J.P., Miller, D.B., Petrovitch, H., Burchfiel, C.M., Sharp,
967 D.S., Markesbery, W.R., Davis, D.G., Hardman, J., et al. (2004). Associations of cortical astrogliosis
968 with cognitive performance and dementia status. *J Alzheimers Dis* *6*, 595-604; discussion 673-581.
969 10.3233/jad-2004-6604.
- 970 35. Boyd, T.D., Bennett, S.P., Mori, T., Governatori, N., Runfeldt, M., Norden, M., Padmanabhan, J.,
971 Neame, P., Wefes, I., Sanchez-Ramos, J., et al. (2010). GM-CSF upregulated in rheumatoid arthritis
972 reverses cognitive impairment and amyloidosis in Alzheimer mice. *J Alzheimers Dis* *21*, 507-518.
973 10.3233/jad-2010-091471.
- 974 36. Kiyota, T., Machhi, J., Lu, Y., Dyavarshetty, B., Nemati, M., Yokoyama, I., Mosley, R.L., and
975 Gendelman, H.E. (2018). Granulocyte-macrophage colony-stimulating factor neuroprotective
976 activities in Alzheimer's disease mice. *J Neuroimmunol* *319*, 80-92. 10.1016/j.jneuroim.2018.03.009.
- 977 37. Castellano, J.M., Mosher, K.I., Abbey, R.J., McBride, A.A., James, M.L., Berdnik, D., Shen, J.C.,
978 Zou, B., Xie, X.S., Tingle, M., et al. (2017). Human umbilical cord plasma proteins revitalize
979 hippocampal function in aged mice. *Nature* *544*, 488-492. 10.1038/nature22067.
- 980 38. Ahmed, M.M., Wang, A.C., Elos, M., Chial, H.J., Sillau, S., Solano, D.A., Coughlan, C., Aghili, L.,
981 Anton, P., Markham, N., et al. (2022). The innate immune system stimulating cytokine GM-CSF
982 improves learning/memory and interneuron and astrocyte brain pathology in Dp16 Down syndrome
983 mice and improves learning/memory in wild-type mice. *Neurobiol Dis* *168*, 105694.
984 10.1016/j.nbd.2022.105694.
- 985 39. Cohen, R.M., Rezai-Zadeh, K., Weitz, T.M., Rentsendorj, A., Gate, D., Spivak, I., Bholat, Y.,
986 Vasilevko, V., Glabe, C.G., Breunig, J.J., et al. (2013). A transgenic Alzheimer rat with plaques, tau
987 pathology, behavioral impairment, oligomeric $\text{A}\beta$, and frank neuronal loss. *J Neurosci* *33*, 6245-6256.
988 10.1523/jneurosci.3672-12.2013.
- 989 40. Rohn, T.T., and Head, E. (2008). Caspase activation in Alzheimer's disease: early to rise and late to
990 bed. *Rev Neurosci* *19*, 383-393. 10.1515/revneuro.2008.19.6.383.
- 991 41. Means, J.C., Gerdes, B.C., Kaja, S., Sumien, N., Payne, A.J., Stark, D.A., Borden, P.K., Price, J.L.,
992 and Koulen, P. (2016). Caspase-3-Dependent Proteolytic Cleavage of Tau Causes Neurofibrillary
993 Tangles and Results in Cognitive Impairment During Normal Aging. *Neurochem Res* *41*, 2278-2288.
994 10.1007/s11064-016-1942-9.
- 995 42. Zhang, P., Kishimoto, Y., Grammatikakis, I., Gottimukkala, K., Cutler, R.G., Zhang, S.,
996 Abdelmohsen, K., Bohr, V.A., Misra Sen, J., Gorospe, M., and Mattson, M.P. (2019). Senolytic
997 therapy alleviates $\text{A}\beta$ -associated oligodendrocyte progenitor cell senescence and cognitive deficits in
998 an Alzheimer's disease model. *Nat Neurosci* *22*, 719-728. 10.1038/s41593-019-0372-9.
- 999 43. Potter, H., and Wisniewski, T. (2012). Apolipoprotein e: essential catalyst of the Alzheimer amyloid
000 cascade. *Int J Alzheimers Dis* *2012*, 489428. 10.1155/2012/489428.

- 001 44. Rogers, J.T., Leiter, L.M., McPhee, J., Cahill, C.M., Zhan, S.S., Potter, H., and Nilsson, L.N. (1999).
002 Translation of the alzheimer amyloid precursor protein mRNA is up-regulated by interleukin-1
003 through 5'-untranslated region sequences. *J Biol Chem* 274, 6421-6431. 10.1074/jbc.274.10.6421.
- 004 45. Gage, F.H. (2019). Adult neurogenesis in mammals. *Science* 364, 827-828. 10.1126/science.aav6885.
- 005 46. Alves, F., Kallinowski, P., and Ayton, S. (2023). Accelerated Brain Volume Loss Caused by Anti- β -
006 Amyloid Drugs: A Systematic Review and Meta-analysis. *Neurology*.
007 10.1212/wnl.0000000000207156.
- 008 47. Salloway, S., Chalkias, S., Barkhof, F., Burkett, P., Barakos, J., Purcell, D., Suhy, J., Forrestal, F.,
009 Tian, Y., Umans, K., et al. (2022). Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies
010 Evaluating Aducanumab in Patients With Early Alzheimer Disease. *JAMA Neurol* 79, 13-21.
011 10.1001/jamaneurol.2021.4161.
- 012 48. Kim, N.K., Choi, B.H., Huang, X., Snyder, B.J., Bukhari, S., Kong, T.H., Park, H., Park, H.C., Park,
013 S.R., and Ha, Y. (2009). Granulocyte-macrophage colony-stimulating factor promotes survival of
014 dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced murine
015 Parkinson's disease model. *Eur J Neurosci* 29, 891-900. 10.1111/j.1460-9568.2009.06653.x.
- 016 49. Kelso, M.L., Elliott, B.R., Haverland, N.A., Mosley, R.L., and Gendelman, H.E. (2015). Granulocyte-
017 macrophage colony stimulating factor exerts protective and immunomodulatory effects in cortical
018 trauma. *J Neuroimmunol* 278, 162-173. 10.1016/j.jneuroim.2014.11.002.
- 019 50. Kong, T., Choi, J.K., Park, H., Choi, B.H., Snyder, B.J., Bukhari, S., Kim, N.K., Huang, X., Park,
020 S.R., Park, H.C., and Ha, Y. (2009). Reduction in programmed cell death and improvement in
021 functional outcome of transient focal cerebral ischemia after administration of granulocyte-
022 macrophage colony-stimulating factor in rats. Laboratory investigation. *J Neurosurg* 111, 155-163.
023 10.3171/2008.12.JNS08172.
- 024 51. Schneider, U.C., Schilling, L., Schroeck, H., Nebe, C.T., Vajkoczy, P., and Woitzik, J. (2007).
025 Granulocyte-macrophage colony-stimulating factor-induced vessel growth restores cerebral blood
026 supply after bilateral carotid artery occlusion. *Stroke* 38, 1320-1328.
027 10.1161/01.STR.0000259707.43496.71.
- 028 52. Jim, H.S., Boyd, T.D., Booth-Jones, M., Pidala, J., and Potter, H. (2012). Granulocyte Macrophage
029 Colony Stimulating Factor Treatment is Associated with Improved Cognition in Cancer Patients.
030 *Brain Disord Ther J*. 10.4172/bdt.1000101.
- 031 53. Olson, K.E., Abdelmoaty, M.M., Namminga, K.L., Lu, Y., Obaro, H., Santamaria, P., Mosley, R.L.,
032 and Gendelman, H.E. (2023). An open-label multiyear study of sargramostim-treated Parkinson's
033 disease patients examining drug safety, tolerability, and immune biomarkers from limited case
034 numbers. *Transl Neurodegener* 12, 26. 10.1186/s40035-023-00361-1.
- 035 54. Krieger, M., Both, M., Kranig, S.A., Pitzer, C., Klugmann, M., Vogt, G., Draguhn, A., and Schneider,
036 A. (2012). The hematopoietic cytokine granulocyte-macrophage colony stimulating factor is
037 important for cognitive functions. *Sci Rep* 2, 697. 10.1038/srep00697.
- 038 55. Buschmann, I.R., Busch, H.J., Mies, G., and Hossmann, K.A. (2003). Therapeutic induction of
039 arteriogenesis in hypoperfused rat brain via granulocyte-macrophage colony-stimulating factor.
040 *Circulation* 108, 610-615. 10.1161/01.CIR.0000074209.17561.99.
- 041 56. Choi, J.K., Kim, K.H., Park, H., Park, S.R., and Choi, B.H. (2011). Granulocyte macrophage-colony
042 stimulating factor shows anti-apoptotic activity in neural progenitor cells via JAK/STAT5-Bcl-2
043 pathway. *Apoptosis* 16, 127-134. 10.1007/s10495-010-0552-2.
- 044 57. Huang, X., Choi, J.K., Park, S.R., Ha, Y., Park, H., Yoon, S.H., Park, H.C., Park, J.O., and Choi, B.H.
045 (2007). GM-CSF inhibits apoptosis of neural cells via regulating the expression of apoptosis-related
046 proteins. *Neurosci Res* 58, 50-57. 10.1016/j.neures.2007.01.015.
- 047 58. Krüger, C., Laage, R., Pitzer, C., Schäbitz, W.R., and Schneider, A. (2007). The hematopoietic factor
048 GM-CSF (granulocyte-macrophage colony-stimulating factor) promotes neuronal differentiation of
049 adult neural stem cells in vitro. *BMC Neurosci* 8, 88. 10.1186/1471-2202-8-88.

- 050 59. Wu, Y.C., Wen, Q., Thukral, R., Yang, H.C., Gill, J.M., Gao, S., Lane, K.A., Meier, T.B., Riggen,
051 L.D., Harezlak, J., et al. (2023). Longitudinal Associations Between Blood Biomarkers and White
052 Matter MRI in Sport-Related Concussion: A Study of the NCAA-DoD CARE Consortium. *Neurology*
053 *101*, e189-e201. 10.1212/wnl.0000000000207389.
- 054 60. Potter, H., Chial, H.J., Caneus, J., Elos, M., Elder, N., Borysov, S., and Granic, A. (2019).
055 Chromosome Instability and Mosaic Aneuploidy in Neurodegenerative and Neurodevelopmental
056 Disorders. *Front Genet* *10*, 1092. 10.3389/fgene.2019.01092.
- 057 61. Gorgoulis, V., Adams, P.D., Alimonti, A., Bennett, D.C., Bischof, O., Bishop, C., Campisi, J.,
058 Collado, M., Evangelou, K., Ferbeyre, G., et al. (2019). Cellular Senescence: Defining a Path
059 Forward. *Cell* *179*, 813-827. 10.1016/j.cell.2019.10.005.
- 060 62. Herdy, J.R., Traxler, L., Agarwal, R.K., Karbacher, L., Schlachetzki, J.C.M., Boehnke, L., Zangwill,
061 D., Galasko, D., Glass, C.K., Mertens, J., and Gage, F.H. (2022). Increased post-mitotic senescence in
062 aged human neurons is a pathological feature of Alzheimer's disease. *Cell Stem Cell* *29*, 1637-
063 1652.e1636. 10.1016/j.stem.2022.11.010.
- 064 63. Chaib, S., Tchkonja, T., and Kirkland, J.L. (2022). Cellular senescence and senolytics: the path to the
065 clinic. *Nat Med* *28*, 1556-1568. 10.1038/s41591-022-01923-y.
- 066 64. Araya, P., Kinning, K.T., Coughlan, C., Smith, K.P., Granrath, R.E., Enriquez-Estrada, B.A., Worek,
067 K., Sullivan, K.D., Rachubinski, A.L., Wolter-Warmerdam, K., et al. (2022). IGF1 deficiency
068 integrates stunted growth and neurodegeneration in Down syndrome. *Cell Rep* *41*, 111883.
069 10.1016/j.celrep.2022.111883.
- 070 65. Zhang, M., Chen, M.Y., Wang, S.L., Ding, X.M., Yang, R., Li, J., and Jiang, G.H. (2022). Association
071 of Ubiquitin C-Terminal Hydrolase-L1 (Uch-L1) serum levels with cognition and brain energy
072 metabolism. *Eur Rev Med Pharmacol Sci* *26*, 3656-3663. 10.26355/eurrev_202205_28861.
- 073 66. Papa, L., Brophy, G.M., Welch, R.D., Lewis, L.M., Braga, C.F., Tan, C.N., Ameli, N.J., Lopez, M.A.,
074 Haeussler, C.A., Mendez Giordano, D.I., et al. (2016). Time Course and Diagnostic Accuracy of Glial
075 and Neuronal Blood Biomarkers GFAP and UCH-L1 in a Large Cohort of Trauma Patients With and
076 Without Mild Traumatic Brain Injury. *JAMA Neurol* *73*, 551-560. 10.1001/jamaneurol.2016.0039.
- 077 67. Hicks, C., Dhiman, A., Barrymore, C., and Goswami, T. (2022). Traumatic Brain Injury Biomarkers,
078 Simulations and Kinetics. *Bioengineering (Basel)* *9*. 10.3390/bioengineering9110612.
- 079 68. Wang, Y. (2011). *Smoothing Splines: Methods and Applications* (CRC Press: Taylor & Francis
080 Group. A Chapman & Hall Book).
- 081 69. Czeiter, E., Amrein, K., Gravesteyn, B.Y., Lecky, F., Menon, D.K., Mondello, S., Newcombe, V.F.J.,
082 Richter, S., Steyerberg, E.W., Vyvere, T.V., et al. (2020). Blood biomarkers on admission in acute
083 traumatic brain injury: Relations to severity, CT findings and care path in the CENTER-TBI study.
084 *EBioMedicine* *56*, 102785. 10.1016/j.ebiom.2020.102785.
- 085 70. Bazarian, J.J., Biberthaler, P., Welch, R.D., Lewis, L.M., Barzo, P., Bogner-Flatz, V., Gunnar
086 Brolinson, P., Büki, A., Chen, J.Y., Christenson, R.H., et al. (2018). Serum GFAP and UCH-L1 for
087 prediction of absence of intracranial injuries on head CT (ALERT-TBI): a multicentre observational
088 study. *Lancet Neurol* *17*, 782-789. 10.1016/s1474-4422(18)30231-x.
- 089
090
091
092